Severe piperacillin-tazobactam-induced hemolysis in a cystic fibrosis patient.

Andrew D KerkhoffLauren PatrickPatricia CornettMary-Ellen KleinhenzSam Brondfield

Published in: Clinical case reports (2017)

Piperacillin-tazobactam is one of the most common causes of drug-induced immune hemolytic anemia (DIIHA) and is frequently utilized, especially in patients with cystic fibrosis (CF). Here, we report a case of life-threatening piperacillin-tazobactam-associated DIIHA in a 30-year-old woman with CF and propose management recommendations for piperacillin-tazobactam-associated DIIHA in CF patients.

Keyphrases

cystic fibrosis
drug induced
end stage renal disease
chronic kidney disease
ejection fraction
pseudomonas aeruginosa
prognostic factors
patient reported outcomes
early onset
diabetic rats
adverse drug